The CFO of GenMark (NASDAQ: GNMK) is Selling SharesBy Carrie Williams
Following Scott Mendel’s last GNMK Sell transaction on February 22, 2016, the stock climbed by 7.4%. In addition to Scott Mendel, 9 other GNMK executives reported Sell trades in the last month.
Based on GenMark’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.81 million and GAAP net loss of $12.06 million. In comparison, last year the company earned revenue of $8.47 million and had a GAAP net loss of $11.39 million. The company has a one year high of $13.29 and a one year low of $4.20. Currently, GenMark has an average volume of 219.8K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $15.67, reflecting a -20.0% downside.
In the last 30 days, insiders have sold $337.7K worth of GNMK shares and purchased $25K worth of GNMK shares. The insider sentiment on GenMark has been negative according to 94 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which is focused on developing and commercializing its proprietary eSensor detection technology. The company’s eSensor electrochemical technology enables fast, accurate and highly sensitive detection of multiple distinct biomarkers in a single sample. GenMark Diagnostics was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.